, Volume 41, Issue 3, pp 731–734 | Cite as

Raltegravir resistance in the cerebrospinal fluid

Case Report


We report the first published case of integrase inhibitor resistance in the central nervous system compartment in the absence of evidence of integrase inhibitor resistance in the plasma of a patient without human immunodeficiency virus (HIV)-encephalitis in the context of other HIV-associated central nervous system infections.


Raltegravir Integrase inhibitor Resistance Cerebrospinal fluid Central nervous system 



The authors would like to thank the patient, the nursing and pharmacy staff at the department of HIV and Genitourinary Medicine at St Mary’s Hospital (Imperial College Healthcare NHS Trust, London, UK) and at the Department of HIV, Immunology and Infectious Diseases at St Vincent’s Hospital (Sydney, Australia).

Conflict of interest

AW has received honoraria or research grants, or been a consultant or investigator, in clinical trials sponsored by Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Janssen Cilag, Roche, Pfizer and ViiV Healthcare. All remaining authors declare no conflicts of interest.


  1. 1.
    Rawson T, Muir D, Mackie NE, Garvey LJ, Everitt A, Winston A. Factors associated with cerebrospinal fluid HIV RNA in HIV infected subjects undergoing lumbar puncture examination in a clinical setting. J Infect. 2012;65:239–45.PubMedCrossRefGoogle Scholar
  2. 2.
    Cunningham PH, Smith DG, Satchell C, Cooper DA, Brew B. Evidence for independent development of resistance to HIV-1 reverse transcriptase inhibitors in the cerebrospinal fluid. Aids. 2000;14:1949–54.PubMedCrossRefGoogle Scholar
  3. 3.
    geno2pheno[resistance]. GENAFOR (Gesellschaft für nachhaltige Forschung). Max Planck Institute. Available at: Accessed 29 Jan 2013
  4. 4.
    Watanabe K, Honda M, Watanabe T, et al. Emergence of raltegravir-resistant HIV-1 in the central nervous system. Int J STD AIDS. 2010;21:840–1.PubMedCrossRefGoogle Scholar
  5. 5.
    Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med. 2008;359:355–65.PubMedCrossRefGoogle Scholar
  6. 6.
    Antinori A, Giancola ML, Grisetti S, et al. Factors influencing virological response to antiretroviral drugs in cerebrospinal fluid of advanced HIV-1-infected patients. Aids. 2002;16:1867–76.PubMedCrossRefGoogle Scholar
  7. 7.
    Christo PP, Greco DB, Aleixo AW, Livramento JA. Factors influencing cerebrospinal fluid and plasma HIV-1 RNA detection rate in patients with and without opportunistic neurological disease during the HAART era. BMC Infect Dis. 2007;7:147.PubMedCrossRefGoogle Scholar
  8. 8.
    Eden A, Fuchs D, Hagberg L, et al. HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis. 2010;202:1819–25.PubMedCrossRefGoogle Scholar
  9. 9.
    de Almeida SM, Bhatt A, Riggs PK, et al. Cerebrospinal fluid human immunodeficiency virus viral load in patients with neurosyphilis. J Neurovirol. 2010;16:6–12.PubMedCrossRefGoogle Scholar
  10. 10.
    Sinclair E, Ronquillo R, Lollo N, et al. Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection. J Acquir Immune Defic Syndr. 2008;47:544–52.PubMedCrossRefGoogle Scholar
  11. 11.
    Soulie C, Fourati S, Lambert-Niclot S, et al. HIV genetic diversity between plasma and cerebrospinal fluid in patients with HIV encephalitis. Aids. 2010;24:2412–4.PubMedGoogle Scholar
  12. 12.
    Spudich SS, Huang W, Nilsson AC, et al. HIV-1 chemokine coreceptor utilization in paired cerebrospinal fluid and plasma samples: a survey of subjects with viremia. J Infect Dis. 2005;191:890–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Yilmaz A, Gisslen M, Spudich S, et al. Raltegravir cerebrospinal fluid concentrations in HIV-1 infection. PLoS ONE. 2009;4:e6877.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  1. 1.Department of Medicine, Faculty of MedicineImperial College LondonLondonUK
  2. 2.Department of HIV, Immunology and Infectious DiseasesSt Vincent’s HospitalSydneyAustralia
  3. 3.Clinical Trials, St Mary’s HospitalImperial College LondonLondonUK

Personalised recommendations